Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  2017-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1080/00498254.2016.1204567PMID 27435571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methylation, Glucuronidation, and Sulfonation of Daphnetin in Human Hepatic Preparations In Vitro: Metabolic Profiling, Pathway Comparison, and Bioactivity Analysis.

  2016cited by this paper
• Structural Modifications at the C-4 Position Strongly Affect the Glucuronidation of 6,7-Dihydroxycoumarins

  2015cited by this paper
• In Vitro Evaluation of the Effect of 7-Methyl Substitution on Glucuronidation of Daphnetin: Metabolic Stability, Isoform Selectivity, and Bioactivity Analysis.

  2015cited by this paper
• Pharmacological profile of opicapone, a third‐generation nitrocatechol catechol‐O‐methyl transferase inhibitor, in the rat

  2015cited by this paper
• Structure‐based drug design of catechol‐O‐methyltransferase inhibitors for CNS disorders

  2014cited by this paper
• Identification and characterization of human UDP-glucuronosyltransferases responsible for the glucuronidation of fraxetin.

  2014cited by this paper
• New insights for the risk of bisphenol A: inhibition of UDP-glucuronosyltransferases (UGTs).

  2013cited by this paper
• Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma

  2013cited by this paper
• Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders.

  2013cited by this paper
• Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors.

  2011cited by this paper
• Application and potential of capillary electroseparation methods to determine antioxidant phenolic compounds from plant food material.

  2010cited by this paper
• Coumarins: old compounds with novel promising therapeutic perspectives.

  2010cited by this paper
• Identification and Characterization of Human UDP-Glucuronosyltransferases Responsible for the In Vitro Glucuronidation of Daphnetin

  2010cited by this paper
• Rapid Metabolite Profiling of in vivo Metabolites of Escultin in Rat Using Ultra-Fast Liquid Chromatography Combined with Tandem Mass Spectrometry

  2010cited by this paper
• Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel

  2009cited by this paper
• Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor.

  2009influential reference
• The structure and pharmacological functions of coumarins and their derivatives.

  2009cited by this paper
• Evolution and current status of research in phenolic compounds.

  2007cited by this paper
• Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies.

  2005cited by this paper
• In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.

  2003cited by this paper
• Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models.

  2003cited by this paper
• Characterization of catechol glucuronidation in rat liver.

  2002cited by this paper
• Entacapone‐Induced Hepatotoxicity and Hepatic Dysfunction

  2002cited by this paper
• SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold.

  2002cited by this paper
• AdoMet-dependent methylation, DNA methyltransferases and base flipping.

  2001cited by this paper
• Coumarin derivatives with COMT inhibiting activity

  2001cited by this paper
• Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.

  2001cited by this paper
• Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

  1999influential reference
• Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.

  1999influential reference
• Management of early Parkinson's disease.

  1999cited by this paper
• Tolcapone and fulminant hepatitis.

  1998cited by this paper
• Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

  1995cited by this paper
• Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters.

  1994cited by this paper
• The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.

  1993cited by this paper
• Cloning and Characterization of Human Placental Catechol--Methyltransferase cDNA

  1991cited by this paper
• Coumarin derivatives

  1990cited by this paper
• [Metabolism and pharmacokinetics of daphnetin].

  1983influential reference
• Metabolism and pharmacokinetics of daphnetin

  1983cited by this paper

• An activity‐based sensing fluorogenic probe for monitoring O‐methyltransferase in plants

  2024cites this paper
• Recent Methods for Synthesis of Coumarin Derivatives and Their New Applications

  2023cites this paper
• Coumarin-based near-infrared fluorogenic probes: Recent advances, challenges and future perspectives

  2023cites this paper
• A comparative investigation of catalytic mechanism and domain between catechol-O-methyltransferase isoforms by isomeric shikonin and alkannin.

  2023cites this paper
• Mechanistic interplay of various mediators involved in mediating the neuroprotective effect of daphnetin

  2021cites this paper
• Search for safer and potent natural inhibitors of Parkinson's disease.

  2021cites this paper
• Accurate and sensitive detection of Catechol-O-methyltransferase activity by liquid chromatography with fluorescence detection.

  2020cites this paper
• Analytical methodologies for sensing catechol-O-methyltransferase activity and their applications

  2020cites this paper
• Botanical Therapeutics for Parkinson’s Disease

  2020cites this paper
• Liver says no: the ongoing search for safe catechol O-methyltransferase inhibitors to replace tolcapone.

  2020cites this paper
• Xanthotoxin reverses Parkinson’s disease-like symptoms in zebrafish larvae and mice models: a comparative study

  2020cites this paper
• 5‐HTTLPR and COMT Val158Met are not associated with alexithymia: New evidence and meta‐analyses

  2019cites this paper
• An Optimized Two-Photon Fluorescent Probe for Biological Sensing and Imaging of Catechol-O-Methyltransferase.

  2017cites this paper